Just In
- 7 hrs ago Anant Ambani-Radhika Merchant's Wedding Function Details Are Out, Check out Ambani Bahu-To-Be's Chic Fashion!
- 8 hrs ago Nayanthara Poses With Husband Vignesh Shivan In Chic Saree, Check Her Sarees To Ace Summer Wedding Look
- 12 hrs ago Hanuman Jayanti 2024: These Are Lord Hanuman's Favourite Zodiac Signs, Check Out The List!
- 13 hrs ago Arushi Sharma-Vaibhav Vishant Wedding, Love Aaj Kal 2 Actor Looks Resplendent In A Pastel Ethnic Outfit, Pics!
Don't Miss
- Sports Who Won Yesterday's IPL Match 39? CSK vs LSG, IPL 2024 on April 23: Marcus Stoinis Fires 63-ball 124 To Quiet Chepauk
- News Senator Lambie Calls For Elon Musk's Imprisonment Over Wakeley Church Stabbing Posts
- Movies Mirzapur 3 OTT Release Date, Platform: When Will Mirzapur Season 3 Premiere On Amazon Prime Video?
- Finance 25% Dividend Record Date: Logistic Stock Nears 1-Year High And It Belongs To Mahindra; Motilal Neutral
- Education Telangana Inter Manabadi 1st and 2nd Year Results 2024 to be Declared Tomorrow
- Automobiles Chrysler Pacifica Marks Seven Years As Most Awarded Minivan With New Campaign
- Technology Xiaomi Robot Vacuum Cleaner S10, Handheld Garment Steamer, and Redmi Buds 5A Launched in India
- Travel Kurnool's Hidden Gems: A Guide To Exploring India's Lesser-Known Treasures
Bharat Biotech Submits Clinical Trial Data Of Covaxin In Children To CDSCO
Bharat Biotech, which completed the Phase 2/3 trials of Covid-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday.
"Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO. This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults," sources told PTI.
Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on.
As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.
"We will be submitting the data (to the regulator) by next week," he had said.
He also had said that Phase 2 trials of an intranasal vaccine to prevent Covid-19 were going on and expected to be over in October.
If approved, Covaxin will be the first Covid-19 vaccine that can be administered to children in India.
- wellnessWe Are Able To Predict Pandemic Based On Changes In Virus, Other Signals: Bharat Biotech Founder
- wellnessTemporarily Slowing Down Production Of Covaxin: Bharat Biotech
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthNeglected Infectious Diseases May Be Tomorrow's Pandemic: Bharat Biotech Chief Dr Krishna Ella
- healthIndia-Made Covaxin Now On UK's Approved Travel List
- healthBharat Biotech Completes Phase 2/3 Trials Of Covaxin for Children Under 18 Years
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval